Prevalence of Bronchiectasis in COPD Patients

Study Overview
=================
Brief Summary
-----------------
The identification of bronchiectasis in COPD has been defined as a different clinical COPD phenotype with greater symptomatic severity, more frequent chronic bronchial infection and exacerbations, and poor prognosis. A causal association has not yet been proven, but it is biologically plausible that COPD, and particularly the infective and exacerbator COPD phenotypes, could be the cause of bronchiectasis without any other known etiology, beyond any mere association or comorbidity.

Detailed Description
-----------------
The relationship between bronchiectasis and COPD has generated several questions. Is there any real increased prevalence of bronchiectasis in patients with COPD? Does the presence of bronchiectasis have an impact on the clinical characteristics, prognosis, or response to treatment in COPD, to the extent that it can be considered a distinct clinical phenotype? Should bronchiectasis in patients with COPD be seen as merely a comorbidity, or as a consequence of the disease's natural history? Is there a causal relationship between COPD and bronchiectasis? If this is the case, what are the pathophysiological mechanisms responsible for this relationship? And, finally, what is the role of chronic bronchial infection and exacerbations in this relationship?

Official Title
-----------------
Prevalence of and Prognostic Impact of Bronchiectasis in COPD Patients

Conditions
-----------------
Bronchiectasis, Chronic Obstruct Airways Disease, Prognosis

Intervention / Treatment
-----------------
* Other: prevalence


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COPD patients based on GOLD 2019 criteria, stable or in exacerbation Exclusion Criteria: acute pneumonia within 2 months malignancy congenital bronchiectasis ( immobile cilia syndrome, Kartagnar syndrome). Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>COPD patients with bronchiectasis | Other: prevalence<br>* percentage of bronchectasis in COPD and its effect as prognostic measure<br>|
| Group B<br>COPD patients without bronchiectasis | Other: prevalence<br>* percentage of bronchectasis in COPD and its effect as prognostic measure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Bronchiectasis in COPD | percentage of bronchiectasis diagnosed by CT chest in COPD patients | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| impact of bronchiectasis on COPD exacerbations | number of exacerbations treated in or out of hospitals | 1 year | 
| impact of bronchiectasis on COPD hospitalization | number of hospital admissions with acute exacerbations | 1 year | 
| impact of bronchiectasis on COPD intensive care admission | number of admissions in respiratory ICU and need for mechanical or non invasive ventilation | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bronchiectasis, COPD, Prevalence, Prognosis